Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Executive summary

Conclusions

1 evidence topic · 15 sources

Summary

Lorundrostat is an investigational oral aldosterone synthase inhibitor developed by Mineralys Therapeutics. Mineralys submitted a New Drug Application to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”, and the application is under review with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. No prescribing information, approved dose, or price is available; on its third quarter 2026 earnings call, the company stated that “we haven't finalized the price yet”. Baxdrostat (BAXFENDY, AstraZeneca), an aldosterone synthase inhibitor, was approved by the FDA on May 15, 2026 for the treatment of hypertension in combination with other antihypertensive drugs in adults who are not adequately controlled on other agents, and lorundrostat would be the second approved drug of the class.

The efficacy evidence comes from two placebo-controlled trials that the company describes as pivotal, both in adults with uncontrolled hypertension taking 2 to 5 antihypertensive medications. In the phase 3 Launch-HTN trial (1,083 participants randomized, including participants with treatment-resistant hypertension), lorundrostat 50 mg daily added to existing therapy changed automated office systolic blood pressure at week 6 by −16.9 mm Hg against −7.9 mm Hg with placebo, a difference of −9.1 mm Hg (95% CI, −13.3 to −4.9; P < .001), and 44.1% of participants receiving lorundrostat and 24.1% receiving placebo reached an office systolic blood pressure below 130 mm Hg; the placebo-adjusted change at week 12 in the 50 mg group, an exploratory outcome, was −11.6 mm Hg. In the phase 2 Advance-HTN trial (285 participants randomized after a switch to a standardized background regimen), the placebo-adjusted change in 24-hour ambulatory systolic blood pressure at week 12 was −7.9 mm Hg with lorundrostat 50 mg and −6.5 mm Hg with a 50 to 100 mg dose-adjustment strategy. In both trials, escalation from 50 mg to 100 mg gave no additional reduction in blood pressure. In Explore-CKD, 59 participants with chronic kidney disease and albuminuria were randomized, and lorundrostat 25 mg changed automated office systolic blood pressure by −7.5 mm Hg relative to placebo over a 4-week crossover period.

Placebo-controlled data extend to 12 weeks. In the Transform-HTN open-label extension, 632 of the 808 Launch-HTN participants who received lorundrostat (78%) enrolled; the change in office systolic blood pressure from the Launch-HTN baseline to week 48 was −17.8 mmHg (95% CI, −19.6 to −16.0), a within-group change with no concurrent control group, and 56.0% of participants had an office systolic blood pressure below 130 mmHg at week 48. These results are available as congress slides and a company press release.

Hyperkalemia, hyponatremia, and an early decrease in eGFR were the adverse events of special interest across trials. In Launch-HTN, serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, and hyperkalemia requiring trial drug modification in 2.6% and 2.0% against 0.4%. In Advance-HTN, potassium above 6.0 mmol/L occurred in 5% and 7% of the two lorundrostat groups and no placebo participants (2.1% and 3.2% after confirmation by repeat testing); in Explore-CKD, hyperkalemia was reported in 15.5% of participants during lorundrostat treatment and 3.5% during placebo; and in Transform-HTN, 2.5% of participants had potassium above 6.0 mmol/L confirmed by repeat testing and 1.6% discontinued lorundrostat for hyperkalemia. Hyponatremia requiring trial drug modification occurred in 10.4% and 6.9% of the Launch-HTN lorundrostat groups and 3.3% of the placebo group, and hyponatremia was reported in 9% and 11% of the Advance-HTN lorundrostat groups and 6% of the placebo group. In Launch-HTN, creatinine-based eGFR decreased by 9.3% from baseline to week 12 with lorundrostat and increased by 0.4% with placebo (cystatin C-based eGFR, decreases of 5.2% and 4.1% against an increase of 3.4%), and the company states that serum potassium increased and eGFR decreased early in treatment and that “both remained stable through the open-label period to Week 48”. Launch-HTN excluded people with an eGFR below 45 mL/min/1.73 m2 or serum potassium above 5.0 mmol/L at screening. The BAXFENDY label directs assessment of serum potassium and serum sodium before initiation and periodically thereafter.

No trial of lorundrostat has measured cardiovascular, kidney, or mortality outcomes, and the BAXFENDY label states for baxdrostat that “There are no controlled trials demonstrating risk reduction of these events”. No head-to-head trial has compared lorundrostat with spironolactone, baxdrostat, or another add-on drug; in a network meta-analysis of 10 trials with 2,865 participants, the mean differences in office systolic blood pressure against placebo were −6.80 mmHg for lorundrostat, −9.09 mmHg for baxdrostat, and −10.78 mmHg for spironolactone. No results were located for the Transform-HTN randomized treatment withdrawal substudy, a registered primary outcome, and the registry record states “No Results Posted”. ICER's evidence report rated the evidence “insufficient” to determine the net health benefits of lorundrostat and baxdrostat compared with each other in all three of its populations, rated either drug “Promising but Inconclusive” compared with spironolactone, eplerenone, or amiloride in Populations 1 and 2, and rated either drug “comparable or inferior” to amlodipine in Population 3. With lorundrostat costed at a placeholder price of $10,950 per year equal to the baxdrostat wholesale acquisition cost, ICER estimated $1,419,000 per QALY gained compared with spironolactone and a health-benefit price benchmark of $760 to $1,600 per year. ICER's final report is scheduled for publication “on or around November 30, 2026”.